Chunghwa Chemical Synthesis & Biotech Co., Ltd. (1762.TW)
TWD 28.8
(-1.54%)
TWD 28.8
(-1.54%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 700 Million TWD | 39.8% |
| 2022 | 500.72 Million TWD | -16.69% |
| 2021 | 601.01 Million TWD | 73284.37% |
| 2020 | 819 Thousand TWD | -99.86% |
| 2019 | 602.7 Million TWD | 6.22% |
| 2018 | 567.44 Million TWD | 0.0% |
| 2017 | 567.44 Million TWD | 467.44% |
| 2016 | 100 Million TWD | -23.08% |
| 2015 | 130 Million TWD | -80.0% |
| 2014 | 650 Million TWD | 20.37% |
| 2013 | 540 Million TWD | 4.85% |
| 2012 | 515 Million TWD | 0.0% |
| 2011 | - TWD | -100.0% |
| 2010 | 20 Million TWD | -91.99% |
| 2009 | 249.8 Million TWD | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q1 | 700 Million TWD | 0.0% |
| 2024 Q2 | 700 Million TWD | 0.0% |
| 2023 Q4 | 700 Million TWD | -0.27% |
| 2023 FY | 700 Million TWD | 39.8% |
| 2023 Q1 | 500.62 Million TWD | -0.02% |
| 2023 Q3 | 701.9 Million TWD | 0.23% |
| 2023 Q2 | 700.26 Million TWD | 39.88% |
| 2022 Q2 | 601.67 Million TWD | 33.1% |
| 2022 Q1 | 452.03 Million TWD | -24.79% |
| 2022 FY | 500.72 Million TWD | -16.69% |
| 2022 Q4 | 500.72 Million TWD | 10.85% |
| 2022 Q3 | 451.7 Million TWD | -24.93% |
| 2021 Q1 | 434 Thousand TWD | -47.01% |
| 2021 FY | 601.01 Million TWD | 73284.37% |
| 2021 Q3 | 401.23 Million TWD | 99.39% |
| 2021 Q4 | 601.01 Million TWD | 49.79% |
| 2021 Q2 | 201.22 Million TWD | 46265.44% |
| 2020 Q3 | 1.27 Million TWD | -10.69% |
| 2020 FY | 819 Thousand TWD | -99.86% |
| 2020 Q1 | 602.03 Million TWD | -0.11% |
| 2020 Q2 | 1.43 Million TWD | -99.76% |
| 2020 Q4 | 819 Thousand TWD | -35.92% |
| 2019 Q3 | 599.95 Million TWD | 19.92% |
| 2019 Q4 | 602.7 Million TWD | 0.46% |
| 2019 FY | 602.7 Million TWD | 6.22% |
| 2019 Q1 | 571.87 Million TWD | 0.78% |
| 2019 Q2 | 500.28 Million TWD | -12.52% |
| 2018 Q1 | 567.44 Million TWD | 0.0% |
| 2018 Q4 | 567.44 Million TWD | 0.0% |
| 2018 Q3 | 567.44 Million TWD | 0.0% |
| 2018 FY | 567.44 Million TWD | 0.0% |
| 2018 Q2 | 567.44 Million TWD | 0.0% |
| 2017 Q2 | 70 Million TWD | -30.0% |
| 2017 Q4 | 567.44 Million TWD | 1318.6% |
| 2017 FY | 567.44 Million TWD | 467.44% |
| 2017 Q3 | 40 Million TWD | -42.86% |
| 2017 Q1 | 100 Million TWD | 0.0% |
| 2016 Q4 | 100 Million TWD | -44.44% |
| 2016 FY | 100 Million TWD | -23.08% |
| 2016 Q3 | 180 Million TWD | 38.46% |
| 2016 Q2 | 130 Million TWD | 0.0% |
| 2016 Q1 | 130 Million TWD | 0.0% |
| 2015 FY | 130 Million TWD | -80.0% |
| 2015 Q2 | 110 Million TWD | 0.0% |
| 2015 Q1 | - TWD | -100.0% |
| 2015 Q4 | 130 Million TWD | 0.0% |
| 2015 Q3 | 130 Million TWD | 18.18% |
| 2014 Q3 | 40 Million TWD | -93.44% |
| 2014 FY | 650 Million TWD | 20.37% |
| 2014 Q4 | 650 Million TWD | 1525.0% |
| 2014 Q2 | 610 Million TWD | 577.78% |
| 2014 Q1 | 90 Million TWD | -83.33% |
| 2013 Q3 | 390 Million TWD | 0.0% |
| 2013 Q4 | 540 Million TWD | 38.46% |
| 2013 FY | 540 Million TWD | 4.85% |
| 2013 Q1 | 402.5 Million TWD | -21.84% |
| 2013 Q2 | 390 Million TWD | -3.11% |
| 2012 FY | 515 Million TWD | 0.0% |
| 2012 Q2 | 635 Million TWD | 0.0% |
| 2012 Q3 | 622.5 Million TWD | -1.97% |
| 2012 Q4 | 515 Million TWD | -17.27% |
| 2012 Q1 | - TWD | 0.0% |
| 2011 Q4 | - TWD | -100.0% |
| 2011 Q2 | 30 Million TWD | 200.0% |
| 2011 Q1 | 10 Million TWD | -50.0% |
| 2011 FY | - TWD | -100.0% |
| 2011 Q3 | 30 Million TWD | 0.0% |
| 2010 FY | 20 Million TWD | -91.99% |
| 2010 Q4 | 20 Million TWD | 0.0% |
| 2009 FY | 249.8 Million TWD | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| Apex Biotechnology Corp. | 116.19 Million TWD | -502.43% |
| Sinphar Pharmaceutical Co.,Ltd. | 1.49 Billion TWD | 53.15% |
| Panion & Bf Biotech Inc. | 125.41 Million TWD | -458.134% |
| GenMont Biotech Incorporation | 20.11 Million TWD | -3380.509% |
| Abnova (Taiwan) Corporation | 2.6 Million TWD | -26812.726% |
| Adimmune Corporation | 1.91 Billion TWD | 63.503% |
| Tanvex BioPharma, Inc. | 1.56 Billion TWD | 55.367% |
| Polaris Group | 352.96 Million TWD | -98.318% |
| Energenesis Biomedical CO.,LTD. | - TWD | -Infinity% |
| UnicoCell Biomed Co., Ltd. | 68.23 Million TWD | -925.851% |
| PELL Bio-Med Technology Co. Ltd. | 147.46 Million TWD | -374.682% |